^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    cobas® KRAS Mutation Test

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    Evidence Level:
    Sensitive: B - Late Trials

    [KRAS mutation-Non Small Cell Lung Cancer-selumetinib]

    Source:
    JAMA
    Test:

    cobas® KRAS Mutation Test

    Title:
    Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
    Excerpt:
    Median progression-free survival was 3.9 months (interquartile range [IQR], 1.5-5.9) with selumetinib + docetaxel and 2.8 months (IQR, 1.4-5.5) with placebo + docetaxel (difference, 1.1 months; hazard ratio [HR], 0.93 [95% CI, 0.77-1.12]; P = .44). Median overall survival was 8.7 months (IQR, 3.6-16.8) with selumetinib + docetaxel and 7.9 months (IQR, 3.8-20.1) with placebo + docetaxel (difference, 0.9 months; HR, 1.05 [95% CI, 0.85-1.30]; P = .64). Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel (difference, 6.4%; odds ratio, 1.61 [95% CI, 1.00-2.62]; P = .05).
    Secondary therapy:
    docetaxel
    DOI:
    10.1001/jama.2017.3438
    Trial ID:
    NCT01933932